湖南尔康制药股份有限公司2024年年度报告摘要

Core Insights - The company has undergone a change in its auditing firm to Tianjian Accounting Firm (Special General Partnership) for the current reporting period [1] - The company plans not to distribute cash dividends or issue bonus shares [2] - The main business for 2024 includes the production and sales of excipients, active pharmaceutical ingredients (APIs), and finished drugs [3] Business Overview - The company is a key player in the pharmaceutical excipients sector, focusing on the continuous R&D of existing and new excipient varieties, meeting diverse procurement needs of downstream formulation clients [4] - The primary excipient products for 2024 include pharmaceutical ethanol, glycerin, modified starch, and composite excipients [4] - The company’s API production for 2024 will feature products such as sulfanilamide and hydroquinone [5][6] - Finished drug products for 2024 will include injections for hemostasis, cough relief, asthma treatment, and various traditional Chinese medicines [6] - The company is also involved in the lithium carbonate sector, which has applications in both the pharmaceutical and industrial fields, with ongoing projects in Nigeria for lithium ore exploration and processing [7] Financial Data and Shareholder Information - The company does not require retrospective adjustments or restatements of previous accounting data [8] - There are no significant discrepancies between the disclosed financial indicators and the quarterly or semi-annual reports [8] - The company has no preferred shareholders or significant changes in the top ten shareholders due to share lending activities [9]